MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A.
Tabouret E, et al. Among authors: viens p.
Oncotarget. 2016 Apr 5;7(14):18531-40. doi: 10.18632/oncotarget.7612.
Oncotarget. 2016.
PMID: 26921265
Free PMC article.
Clinical Trial.